Parkinson’s disease
-
Biohaven Initiates Phase 2/3 Trial for Early Parkinson’s Disease, Testing Brain-Penetrant TYK2/JAK1 Inhibitor Against Neuroinflammation
Biohaven launched a global Phase 2/3 trial for BHV-8000, a first-in-clinic, brain-penetrant TYK2/JAK1 inhibitor, targeting neuroinflammation in Parkinson’s disease. The drug aims to address the underlying cause of disease progression, with no existing disease-modifying therapies currently available. The trial will enroll 550 patients across 13 countries to assess efficacy and safety, utilizing innovative endpoints. BHV-8000 has shown safety and tolerability, with robust brain penetration, representing a potential breakthrough in treating neurodegenerative diseases.
